Inactive Instrument

Other languages Hemispherx BioPharma, Inc Nyse

Equities

End-of-day quote Nyse Other stock markets
- ^USD	-

Apr. 10	AIM Immunotech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer	CI
Apr. 02	Transcript : AIM ImmunoTech Inc., Q4 2023 Earnings Call, Apr 02, 2024

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

AIM Immunotech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer	Apr. 10
AIM ImmunoTech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01
Aim Immunotech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen for the Treatment of Post-COVID Conditions	Feb. 08
AIM ImmunoTech Says First Subject Enrolled in Phase 1b/2 Study of Pancreatic Cancer Combination Therapy	Jan. 22
Kellner Group Issues a Statement to the Shareholders	Jan. 03
Sector Update: Health Care	Dec. 29
AIM ImmunoTech Says Delaware Court Rules in Its Favor, Deeming Activist Group's Board Nominations 'Invalid'	Dec. 29
Sector Update: Health Care Stocks Advance Late Afternoon	Dec. 29
Delaware Court Rules in Favor of AIM ImmunoTech and Upholds Board?s Determination that Activist Group?s Nominations Are Invalid	Dec. 29
AIM ImmunoTech Provides Update Regarding Annual Meeting	Nov. 28
AIM ImmunoTech Gets US Patents for Ampligen Cancer, ME/CFS Treatment Methods	Nov. 27
AIM ImmunoTech Treats Last Participant in Phase 2 Study of Ampligen for Potential Treatment of Post-COVID Fatigue	Nov. 21
AIM ImmunoTech Inc. Completes Treatment of Last Subject in Phase 2 Study Evaluating Ampligen for the Treatment of Post-COVID Conditions	Nov. 21
AIM ImmunoTech Mails Letter to its Shareholders	Nov. 20
AIM ImmunoTech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14
AIM ImmunoTech Announces Publication of Data from Roswell Park Comprehensive Cancer Center Phase 1 Study Evaluating Ampligen	Nov. 14
AIM ImmunoTech Inc. Announces Encouraging Translational Data from Phase 2 Study Evaluating Ampligen for the Treatment of Advanced Recurrent Ovarian Cancer	Nov. 08
AIM ImmunoTech Says Phase 1 Study on Ampligen Confirms Positive Findings for Breast Cancer Treatment	23-09-11
Kellner Group to Proceed with AIM Director Nominations and Proxy Solicitation	23-08-28
AIM ImmunoTech Rejects Director Nomination Notice from Ted D. Kellner	23-08-23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Hemispherx BioPharma, Inc Nyse

Equities

Other languages

Filters